Chronic Kidney Disease Market Expansion Continues, with Forecast Valuation of $95.43 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Chronic Kidney Disease Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The worldwide market for chronic kidney disease has experienced robust expansion lately, set to increase from a valuation of $70.65 billion in the year 2024 to reach $74.87 billion by 2025, reflecting a compound annual growth rate of 6.0%; this upward trajectory during the past period has been fueled by factors such as the widespread prevalence of hypertension and diabetes, an increasing global elderly demographic, adoption of detrimental lifestyle habits, significant gaps in healthcare availability, and ongoing progress in medical technology.

Chronic Kidney Disease Market Size Forecast: What's the Projected Valuation by 2029?
Anticipation surrounds the chronic kidney disease sector, projecting robust expansion ahead; this market is slated to reach a valuation of $95.43 billion by the year 2029, underpinned by a compound annual growth rate (CAGR) of 6.3%, with this upward trajectory being fueled by intensified governmental focus on healthcare policies, advancements in personalized medical treatments, escalating prevalence of obesity, the broader increase in long-term health conditions, and enhanced availability of medical services. Key developments shaping this timeframe encompass proactive measures such as expanded early detection drives, the increasing utilization of remote patient oversight and virtual care platforms, initiatives designed to place greater control in patients' hands, movements toward localized healthcare provision, and the incorporation of dietary management as a therapeutic component.

View the full report here:
https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

What Are the Drivers Transforming the Chronic Kidney Disease Market?
Anticipated expansion in the incidence of renal ailments is projected to be the catalyst for the expansion of the market segment dedicated to chronic kidney disease moving ahead. Renal disorders encompass a collection of pathologies that impact the functional capacity and architectural integrity of the kidneys. Therapies prescribed for kidney ailments serve the dual purpose of regulating hypertension in affected individuals and diminishing protein leakage, thereby aiming to arrest the deterioration of renal function, alleviate attendant symptoms, and avert potential adverse outcomes. As an illustration, data released by the Centers for Disease Control and Prevention, a prominent national health organization in the United States, indicated that as of July 2022, approximately fifteen percent of the US population, equating to roughly 37 million individuals, were living with some form of kidney disease; consequently, this escalating rate of kidney ailments underpins the momentum fueling the expansion within the chronic kidney disease marketplace.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11969&type=smp

What Long-Term Trends Will Define the Future of the Chronic Kidney Disease Market?
A significant development gaining traction within the arena of chronic kidney disease involves advancements in product offerings, as market participants actively pursue novel solutions to secure and enhance their competitive standing; for example, Germany's Bayer introduced the groundbreaking medication Kerendia (finerenone) in August 2022, specifically designed to impede the advancement of CKD among diabetic populations, which represents a pioneering, non-steroidal, selective mineralocorticoid receptor antagonist unlike therapies currently available, functioning by inhibiting the excessive stimulation of the mineralocorticoid receptor (MR) that drives both the worsening of CKD and cardiovascular harm.

Which Segments in the Chronic Kidney Disease Market Offer the Most Profit Potential?
The chronic kidney diseasemarket covered in this report is segmented -

1) By Diagnosis: Blood Test; Urine Test; Imaging Test; Kidney Biopsy
2) By Treatment: Drugs; Dialysis; Kidney Transplant; ACE Inhibitors; Blood Test; Other Treatments
3) By Route of Administration: Oral; Intravenous; Subcutaneous
4) By End-User: Hospital And Clinics; Ambulatory Surgery Centers (ASCs); Dialysis Centers; Other End-Users

Subsegments:
1) By Blood Test: Serum Creatinine Test; Glomerular Filtration Rate (GFR) Test; Blood Urea Nitrogen (BUN) Test; Electrolyte Tests
2) By Urine Test: Urinalysis; 24-hour Urine Collection; Urine Protein Test; Urine Albumin-To-Creatinine Ratio (ACR)
3) By Imaging Test: Ultrasound; CT Scan; MRI; X-ray
4) By Kidney Biopsy: Percutaneous Kidney Biopsy; Open Kidney Biopsy; Laparoscopic Kidney Biopsy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11969&type=smp

Which Firms Dominate the Chronic Kidney Disease Market by Market Share and Revenue in 2025?
Major companies operating in the chronic kidney disease market include Pfizer Inc, Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott laboratories Inc., GlaxoSmithKline PLC, Takeda Pharmaceuticals Ltd., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk AS, Siemens Healthineers AG, AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Beckman Coulter Inc., Kissei Pharmaceutical Co. Ltd., Akebia Therapeutics Inc., Mission Therapeutics Ltd., Tricida Inc., Regulus Therapeutics Inc., Goldfinch Bio Co, Alio Inc., Monogram Health, Strive Health, Maze Therapeutics, ProKidney Corp

Which Regions Offer the Highest Growth Potential in the Chronic Kidney Disease Market?
North America was the largest region in the chronic kidney disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11969

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.